Davis Polk Obtains Stay of Transaction Fee Pilot Rule for NYSE
Davis Polk secured a victory for the New York Stock Exchange (“NYSE”) in an ongoing highly publicized dispute between the three…
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Davis Polk Secures Denial of TRO on behalf of Tezos Stiftung in Securities Class Action
On December 20, 2017, Davis Polk obtained the denial of an application for a temporary restraining order that sought to freeze the assets of its client Tezos Stiftung (or the Tezos…
Davis Polk Achieves Significant Appellate Victory for J.P. Morgan
Davis Polk is representing J.P. Morgan in a state securities fraud litigation pending in Florida state court. On Friday, June 9, 2017, we won a complete reversal of the trial court’s grant…
Citigroup wins complete dismissal of qui tam suit alleging tax fraud
Davis Polk recently achieved a major victory for its client, Citigroup Inc. On May 30, 2017, Justice Charles Ramos of the New York Supreme Court filed a so-ordered oral argument transcript…
Davis Polk Wins Dismissal of RMBS Action for Morgan Stanley
On April 12, 2017, Justice Ramos of the New York Supreme Court, Commercial Division, dismissed with prejudice four complaints filed by Royal Park Investments SA/NV (“Royal Park”) alleging…
Davis Polk Victory in Facebook IPO Litigation
On November 3, 2016, the Second Circuit issued an opinion in an action brought under Section 16(b) of the Exchange Act of 1934 against Morgan Stanley, J.P. Morgan and Goldman Sachs, the…
Victory and Favorable Settlement for Dialog Semiconductors
Davis Polk successfully represented Dialog Semiconductors in litigation related to the earnout provisions in its 2013 acquisition of iWatt. In April 2014, Fortis Advisors—acting on behalf…
Davis Polk Wins Motion to Dismiss in Prosensa Securities Litigation
On May 5, 2015, Davis Polk achieved a total victory in a securities litigation filed against its clients Prosensa Holding N.V. (“Prosensa”) and several of Prosensa’s individual officers and…
Davis Polk Obtains Dismissal for Orexigen Directors in a Stock Compensation Derivative Litigation
Davis Polk represents several current and former directors of Orexigen Therapeutics (the “Company”) in connection with derivative litigation relating to the award of equity compensation. On…
Davis Polk Achieves Major Victory for Morgan Stanley in Section 10(b) Class Action Arising from Subprime Trading Losses
Davis Polk achieved a major victory on behalf of Morgan Stanley and certain of its officers and directors in a Section 10(b) shareholder class action arising from Morgan Stanley’s 2007…